ArticleThoracic cancer2026
Radiological, Molecular, and Pathological Factors Unite: A Model for Predicting Recurrence-Free Survival in Pathological Stage I Lung Adenocarcinoma.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe tumor and node metastasis (TNM) staging and pathological grading systems are currently insufficient for accurately predicting recurrence-free survival (RFS) in patients with pathological stage (p-stage) I lung adenocarcinoma (LUAD). Therefore, there is an urgent need for a more economical and applicable clinical prediction model to assess the risk of recurrence and guide clinical postoperative care.
methodsThis retrospective study included 544 patients with p-stage I LUAD who were randomly allocated to development (272 patients) and validation (272 patients) cohorts. Cox regression and backward model selection were used to develop the prediction model. The predictive performance of the model was then compared with that of the current TNM staging system and two major pathological grading systems. The primary endpoint was RFS.
resultsA total of 79 out of 544 patients with p-stage I LUAD experienced recurrence after surgery. Four risk factors were incorporated into a weighted risk index-high-grade patterns ratio, epidermal growth factor receptor mutation status, spread through air spaces status and consolidation tumor ratio-to establish the "CEHS" RFS prediction model. This model demonstrated superior predictive accuracy compared with existing staging and grading systems. High-risk patients had significantly shorter RFS than low-risk patients did. An online algorithm based on the CEHS model was also developed.
conclusionWe established and validated a novel model that integrates radiological, molecular and pathological features to predict RFS in patients with p-stage I LUAD. This new model exhibited excellent discriminatory power for classifying early-stage LUAD patients at different risks of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.